AI-generated · cited to primary sources · not investment advice
Viyash Scientific (512529) Aug 2025 Filing Analysis
Does management do what it says?
The R&D pipeline has expanded to 17 products as of Q3 FY26. (1 exceeded across 1 tracked commitment)
“We started actually relooking at our R&D expansion. This year, you can see definitely our R&D expansion, both space as well as people. So next year, we will come up with strong CDMO.”
The company has already executed 8 launches in the current year, meeting the annual target within the first half of the fiscal year. (2 met, 1 in progress across 3 tracked commitments)
“And currently, we have around 20-plus products on the pipeline and we are actually expected 10 to 15 products development as well as filing this year as anticipated.”
See the full cited Management analysis of Viyash Scientific
Where does growth come from?
The company successfully cleared 5 regulatory inspections in a single quarter, including US FDA and EU audits, demonstrating high manufacturing standards. (2 steady across 2 signals)
“So we had five regulatory inspections last quarter. In fact, one day, we had two US FDA audits in two sites and one Europe audit in the same month... all went through very well.”
See the full cited Future Growth analysis of Viyash Scientific
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.